HeartSciences announced today that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule. This inclusion falls under assignment APC 5734, a crucial step for the commercialization of the company's products. This approval allows outpatient settings to receive reimbursement for HeartSciences’ MyoVista wav ECG algorithm and MyoVista Insights low ejection fraction algorithm, once they receive FDA clearance.
The payment rate for these AI-ECG technologies is expected to be $125 per procedure. This established reimbursement rate provides a clear financial incentive for healthcare providers to adopt HeartSciences' AI-ECG solutions upon their regulatory approval. CEO Andrew Simpson stated that this represents a significant milestone for commercialization and validates the enormous market opportunity, especially given the widespread use of ECGs in clinical practice.
The company anticipates submitting to the FDA and bringing both its MyoVista wav ECG and MyoVista Insights platform to market in 2025. The CMS reimbursement decision is a foundational element for future revenue streams, positioning HeartSciences to capitalize on the growing demand for advanced cardiac screening tools.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.